Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
HLVX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
16 hours ago
prnewswire.com
18 hours ago
prnewswire.com
18 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.81
vs -0.45
Q4.23
N/A
-0.78
vs -0.56
Q1.24
N/A
-0.97
vs -0.71
Q2.24
N/A
-0.83
vs -0.74
Q3.24
N/A
-0.52
vs -0.81
Q4.24
N/A
-0.35
vs -0.78
Q1.25
N/A
-0.12
vs -0.97
Q2.25
N/A
-0.11
vs -0.83
Q3.25
N/A
-0.12
vs -0.52
Q4.25
N/A
-0.12
vs -0.35
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
2.9M vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 2.9M
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-11%
-0.11
vs -0.07
Q2.23
-13%
-0.13
vs -0.11
Q3.23
-11%
-0.11
vs -0.13
Q4.23
-14%
-0.14
vs -0.11
Q1.24
-20%
-0.20
vs -0.14
Q2.24
-20%
-0.20
vs -0.20
Q3.24
-14%
-0.14
vs -0.20
Q4.24
-22%
-0.22
vs -0.14
Q1.25
-4%
-0.04
vs -0.22
Q2.25
-4%
-0.04
vs -0.04
Institutionnal Ownership
QoQ
Q1.23
61
61
vs 56
9%
Q2.23
54
54
vs 61
-11%
Q3.23
68
68
vs 54
26%
Q4.23
69
69
vs 68
1%
Q1.24
80
80
vs 69
16%
Q2.24
91
91
vs 80
14%
Q3.24
79
79
vs 91
-13%
Q4.24
76
76
vs 79
-4%
Q1.25
81
81
vs 76
7%
Q2.25
73
73
vs 81
-10%
Quote Panel
Key Metrics
Forecast
2026-Revenue
-318%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Hold
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
H.C. Wainwright
downgradePrevious: Not converted
2024-07-09
Now: Neutral
Guggenheim
downgradePrevious: Buy
2024-07-08
Now: Neutral
SVB Leerink
initialisePrevious: Not converted
2022-05-25
Now: Outperform
Guggenheim
initialisePrevious: Not converted
2022-05-24
Now: Buy
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.01 ( -0.24%)
Relative Strenght
63
Volume Buzz
-32%
Earning Acce
Yes
Dist 52w H.
5%Relative Strength
HLVX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
